|
| Baseline characteristics () | |
|
| Age (mean, SD) | 40.5 ± 12.3 years |
| Sex (, %) | (34.8%); male |
| (65.2%); female |
| Disease duration (mean, SD) | 7.9 ± 6.2 years |
| Type of MS (, %) | (66.3%); RRMS |
| (33.7%); progressive MS |
| Time since onset of PMS (mean, SD) | 3.0 ± 2.1 years |
| Baseline EDSS score (mean, SD, range) | 2.25 ± 1.2 (0–6.5) |
| Number of relapses in previous two years (mean, SD, range) | 1.6 ± 1.6 (0–8) |
| Time between last relapse and RTX initiation (median, range) | 3 months (0–20) |
| Median number of RTX infusions (range) | 4 infusions (2–22) |
| Proportion of patients with 2000 mg initial loading dose () | 76.4% () |
| Baseline MRI findings (%, ) | 28% (); stable |
| 36% (); new T2 nonenhancing lesions |
| 36% (); enhancing lesions |
|
| Proportion of patients with prior DMT use (%, ) | 11.2% (); treatment naïve |
| 34.8% (); one previous DMT |
| 30.3% (); 2 previous DMTs |
| 11.2% (); 3 previous DMTs |
| 9.0% (); 4 previous DMTs |
| 1.2% (); 5 previous DMTs |
| 2.3% (); 6 previous DMTs |
|
| Last DMT prior to RTX | 55.7% (); IFN |
| 17.7% (); fingolimod |
| 11.4% (); natalizumab |
| 5.1% (); mitoxantrone |
| 10.1% (); others (AZA, mycophenolate, methotrexate, teriflunomide, cyclophosphamide) |
| |
|
| Reasons for switching to RTX | 87.3% (); inefficacy |
| 5.1% (); positive JCV |
| 2.5% (); adverse events |
| 2.5% (); nonavailability of other DMTs |
| 2.5% (); personal decision |
| RTX treatment duration (mean, SD) | 22.2 ± 24.8 months |
|
